Read customers' case studies, showing success using our peptides
Designing a Malaria Vaccine
Researchers at the Medical Research Council (MRC) in the UK and in the Gambia are working to understand the immune response to Plasmodium, and hope to use this insight to design a vaccine to boost immunity and so reduce the number of deaths from malaria infection; read case study
Sleep after vaccination boosts immunological memory
As part of their study to show how a good night's sleep is essential for the best response to vaccination, Lange et al. used peptide libraries to assess how their study subjects were making an immune response; read case study
Research into Type I Diabetes therapy makes use of PEPscreen® technology
Bresson et al. investigated a novel combined therapy for type I diabetes consisting of treatment with anti-CD3 antibody plus a DNA vaccination with islet auto-antigen glutamic acid decarboxylase 65; read case study
HIV vaccine study in pigs uses PEPscreen® peptides in ELISpot assays
To assess the breadth of T cell response to a novel HIV-1 DNA vaccine encompassing several HIV-1 proteins, Mölder et al. used domestic pigs as an animal model; read case study
PEPscreen® used in vaccine development for Mycobacterium tuberculosis
Roupie et al. generated a PEPscreen® custom peptide library to screen overlapping peptides from two candidate antigens from the MAP protein to identify immunodominant T cell epitopes that could be used as a potential vaccine; read case study.
Custom peptides play a key role in search for cancer therapy
Professor Arun Rishi, Wayne State University USA, has been using thinkpeptides custom peptides in his research to study functions of the apoptosis-associated protein CARP-1, with the ultimate aim of developing small-molecule compounds as cancer therapeutics; read case study.
Custom peptides and improving cancer virotherapy
Ramakrishna et al. investigated potential improvements to virotherapy against tumour targets, including local expression of cytokines to encourage dendritic cell homing to the tumour. They used custom peptides in a range of assays to evaluate the anti-tumour effects they observed; read case study.
Vaccine development relies on thinkpeptides quality
Dr Yared Hailemichael, University of Texas MD Anderson Cancer Center USA, says “I use the B16 melanoma/pmel-1 T cell model to study the requirements for successful vaccination using peptide immunogens. The induction of strong CD8 T cell response requires a sustained presentation of antigen in a stimulatory context to develop into effector cells that can kill tumors through the recognition of tumor antigens bound to MHC-I molecules. It is important to have a high standard of reagents for my mouse vaccination protocols, and I am very satisfied with the quality of peptides and the responsive customer service that thinkpeptides provides.”
thinkpeptides is a brand of ProImmune